Cardiff Oncology, Inc. (CRDF): Submission of Matters to a Vote of Security Holders
Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001213037 false 0001213037 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
How this was made
The 30-second read
Why it matters
The company confirms: (1) all six director nominees were elected, (2) BDO USA, P.C. was ratified as independent auditor for FY ended Dec. 31, 2026, (3) the 2021 Equity Incentive Plan was amended to increase shares issuable to 15,150,000, and (4) the advisory vote on named executive officer compensation was approved.
Market read
Shareholder approvals reduce governance uncertainty but do not introduce new operating catalysts; dilution risk is only indirectly implied by the plan share increase.
What to watch
Traders may still watch for follow-on disclosures tied to the approved equity plan (future grants/issuances), but they are not provided here.
Background
The SEC 8-K Item 5.07 summarizes shareholder voting results from Cardiff Oncology’s annual meeting held June 11, 2026.
Ticker impact
Cardiff Oncology reports final results from its June 11, 2026 annual meeting, including director elections and shareholder votes on auditor and equity plan amendments.
Likely low near-term impact; any move would be sentiment/positioning rather than a new operating catalyst.
The filing discloses voting outcomes but no new clinical, financial, regulatory, or deal information; such items typically have modest trading effect unless tied to major financing or strategic shifts.
Market effects
Minimal; routine governance actions for a biotech do not reset sector expectations.
None indicated.
None indicated.
Counterpoint
Even routine equity-plan share increases can matter for dilution expectations, but this filing provides no details on actual issuance or financing timing.
Key entities
- issuerCardiff Oncology, Inc.
Subject of the SEC 8-K; reports annual meeting voting outcomes.
- auditorBDO USA, P.C.
Independent registered public accounting firm ratified for FY ended Dec. 31, 2026.
- equity_compensation2021 Equity Incentive Plan
Amended to increase shares issuable to 15,150,000, per Proposal 3.
